Overt Hepatic Encephalopathy Market Analysis | 2023-2028

Market Insights

The overt hepatic encephalopathy market was estimated at USD 87.8 million in 2022 and is likely to grow at a CAGR of 10.67% during 2023-2028 to reach USD 161.73 million in 2028.

Want to know more about the market scope? Register Here

Market Dynamics

Introduction

Hepatic encephalopathy is a brain disorder that most commonly occurs in people having chronic liver disease. Its complications could be dysfunction of the brain and may include impaired memory, intellectual impairment, personality changes, and loss of consciousness (coma). Overt hepatic encephalopathy is associated with obvious, outward signs and symptoms in the affected individuals.

COVID-19 Impact on Global Market

The COVID-19 outbreak is projected to have a long-term impact on the growth of overt hepatic encephalopathy as people suffering from cirrhosis disease require intense preventive care which was affected by the spread of coronavirus. It affected the process developed to provide good care to the patients.

Market Drivers

The growth of the global market is primarily driven by the rising number of people having cirrhosis disease.

• Cirrhosis is a chronic liver damage illness that can result in scarring and liver failure.
• Increasing consumption of alcohol has resulted in an increased incidence of liver disease among people.
• This further can lead to overt hepatic encephalopathy illness and thus, drive the market growth.
• Growing emphasis on the development of advanced solutions by the market players is likely to propel the market growth at a significant rate during the review period.

Want to have a closer look at this report, Download a free sample

Key Players

Key players operating in the global market are:

• Alfa Wassermann S.P.A (Italy),
• Rebiotix Inc. (The U.S),
• Cosmo Pharmaceuticals S.P.A (Italy),
• Spherium Biomed S.L (Spain),
• Horizon Pharma Plc (Ireland),
• Umecrine Cognition AB (Sweden),
• Ocera Therapeutics Inc. (The U.S),
• Mallinckrodt Pharmaceuticals (UK),
• Kannalife Sciences Inc. (The U.S),
• Bausch Health Companies Inc. (The U.S),
• ASKA Pharmaceutical Co., Ltd (Japan),
• Norgine BV (Netherlands).

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at [email protected]

Segment Analysis

By Treatment Type

Based on treatment, the market has been segmented into lactulose, antibiotics, probiotics, liver transplantation, and others. The lactulose segment accounted for the largest market share in 2022. The segment growth can be attributed to its ability to reduce ammonia production in the intestine by creating an aggressive for the bad microbes in the intestine.

Regional Insights

Geographically, the market in North America accounted for the largest market share in 2022 and is expected to continue its dominance over the forecast period owing to an increasing number of people suffering from cirrhosis. For instance, around 5.5 million people in the U.S. are affected by cirrhosis and approximately 70% of them are likely to develop symptoms of overt hepatic encephalopathy. The market in the Asia-Pacific region is projected to register the fastest growth during the review period on account of the rising number of people suffering from chronic liver diseases.

Know the high-growth countries in this report. Click Here

Research Methodology

• This strategic assessment report from Stratview Research provides a comprehensive analysis that reflects overt hepatic encephalopathy market realities and future market possibilities for the forecast period.
• The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.
• The vital data/information provided in the report can play a crucial role for market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate growth strategies to expedite their growth process.
• This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
• More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.
• We conducted more than 15 detailed primary interviews with market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market. The following are the key features of the report:

• Market structure: Overview, industry life cycle analysis, supply chain analysis.
• Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
• Market trend and forecast analysis.
• Market segment trend and forecast.
• Competitive landscape and dynamics: Market share, Service portfolio, New Product Launches, etc.
• COVID-19 impact and its recovery curve
• Attractive market segments and associated growth opportunities.
• Emerging trends.
• Strategic growth opportunities for the existing and new players.
• Key success factors.

Market Segmentation

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The overt hepatic encephalopathy market is segmented into the following categories:

By Disease Severity Type

• Type A
• Type B
• Type C

By Diagnosis Type

• Blood Tests
• Liver Function Test
• Encephalogram
• Other

By Treatment Type

• Lactulose
• Antibiotics
• Probiotics
• Liver Transplantation
• Other

By End User Type

• Hospitals & Clinics
• Research Institutes
• Surgical Centers
• Other

By Region

• North America (Country Analysis: the USA, Canada, and Mexico)
• Europe (Country Analysis: Germany, France, the UK, Russia, Spain, and the Rest of Europe)
• Asia-Pacific (Country Analysis: China, Japan, India, South Korea, and the Rest of Asia-Pacific)
• Rest of the World (Sub-Region Analysis: Latin America, the Middle East, and Others)

Want to know the most attractive market segments? Register Here

Report Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to 3 players)
• SWOT analysis of key players (up to 3 players)

Market Segmentation

• Current market segmentation by any one of the disease severity types by treatment type.

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected].